Study of Perfusion and Diffusion Magnetic Resonance Imaging, and Phosphorylation of Circulation Endothelial Cells to Determine Anti-angiogenic Effect in Patients With Colorectal Liver Metastasis in Chemotherapeutic Regimens Including Avastin
The purpose of our study is to establish the accuracy of the perfusion MRI parameters and
the availability of the VEGFR2 signaling assay using phosphospecific flow cytometry in
predicting the response of liver metastasis from colorectal cancer to treatment with
antiangiogenic agent.
IRB approval will be obtained to enroll 60 naïve patients (30 patients who will get
antiangiogenic agent (Avastin) combined chemotherapy and 30 patients who will get
chemotherapy without antiangiogenic agent) with liver metastasis from colorectal cancer. MRI
and blood test (VEGFR2 signaling assay) will be undergoing at three time points in the
patients with Avastin chemotherapy; at baseline (pretreatment), 3 days after Avastin alone
treatment, 3 days after Avastin combined chemotherapy (about 10 days after initial Avastin
alone treatment). MRI and blood test (VEGFR2 signaling assay) will be undergoing at two time
points in the patients who will get chemotherapy without antiangiogenic agent; at baseline
(pretreatment), 3 days after chemotherapy.
Interventional
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
MR perfusion parameter
MR perfusion parameter(Ktrans, Kep, Ve)
3 days after administrating avastin
No
South Korea: Korea Food and Drug Administration (KFDA)
4-2010-0047
NCT01318239
July 2010
April 2012
Name | Location |
---|